The Janssen Pharmaceutical Companies of Johnson & Johnson has decided to withdraw the phase three LOTUS study of STELARA (ustekinumab) in Systemic Lupus Erythematosus (SLE), it was reported on Friday.
The company has taken this step because of the lack of efficacy in SLE.
Interim safety findings for Stelara were consistent with the product's known safety profile and no new safety signals were found.
Investigators, study participants and health authorities have been informed of the decision. The company intends to thoroughly analyse the totality of the study data and publish findings. The company stated that the decision to discontinue the LOTUS study does not impact any other ongoing studies with ustekinumab or current indications.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA